Rapid single-cycle assay for human immunodeficiency virus type-1 drug
resistance
    2.
    发明授权
    Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance 有权
    人类免疫缺陷病毒1型耐药性的快速单循环测定

    公开(公告)号:US6103462A

    公开(公告)日:2000-08-15

    申请号:US129790

    申请日:1998-08-06

    IPC分类号: C12Q1/70

    CPC分类号: C12Q1/70 C12Q1/703

    摘要: An in vitro, single cycle, recombinant virus assay (RVA) for determining inhibition of HIV replication by a protease inhibitor comprises transfecting a human epithelial cell line with amplified HIV protease sequences of an HIV virus; an HIV, envelope defective, molecular clone having a complete deletion of its protease coding sequence; and a plasmid containing HIV envelope coding sequence under the control of a promoter for phenotypic complementation of the envelope defective molecular clone. The transfected cells are cultured in the presence of a protease inhibitor to produce a testable stock of infectious particles that can be used to infect indicator cells containing an indicator gene without amplification of the infectious particles prior to infecting the indicator cells. Accumulation of indicator gene product is a measure of inhibition of HIV replication by the protease inhibitor.

    摘要翻译: 用于测定由蛋白酶抑制剂抑制HIV复制的体外,单周期重组病毒测定(RVA)包括用HIV病毒的扩增的HIV蛋白酶序列转染人上皮细胞系; 具有完整缺失其蛋白酶编码序列的HIV,包膜缺陷的分子克隆; 以及含有在包膜缺陷型分子克隆的表型互补启动子控制下的HIV包膜编码序列的质粒。 转染的细胞在蛋白酶抑制剂的存在下培养以产生感染性颗粒的可测试储备物,其可以在感染指示剂细胞之前不用扩增感染性颗粒来感染含有指示基因的指示细胞。 指标基因产物的积累是蛋白酶抑制剂抑制HIV复制的量度。

    MULTIPLEX IMMUNO SCREENING ASSAY
    3.
    发明申请
    MULTIPLEX IMMUNO SCREENING ASSAY 有权
    多重免疫屏蔽测定

    公开(公告)号:US20140274762A1

    公开(公告)日:2014-09-18

    申请号:US13883339

    申请日:2012-12-10

    IPC分类号: G01N33/543

    摘要: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures. The methods of the invention possess the ability to multiplex, minimize the amount of biological sample, and have enhanced sensitivity and specificity toward target antibodies as compared with classical ELISA or Radio-Immunoprecipitation assays.

    摘要翻译: 本发明提供用于病原体的早期检测,病原体的精确鉴定和改进的疾病监测的试剂盒和测定方法。 更具体地,本发明公开了一种免疫测定,其导致快速和同时检测感染患者生物流体中广泛感染性病原体的抗体。 该免疫测定涉及包含AGT酶和病毒抗原的融合蛋白在可识别的固体支持物(例如荧光微球)上的共价和取向偶联,所述载体预先用AGT底物涂覆。 该偶联由AGT酶在其底物上的不可逆反应介导。 与通过标准胺偶联方法制备的抗原偶联微球相比,由此获得的抗原偶联微球显示出特异性抗体的增强捕获。 与传统的ELISA或放射免疫沉淀测定相比,本发明的方法具有复用多样化,最小化生物样品的量并且对靶抗体具有增强的敏感性和特异性的能力。